Imperagen, a biotech startup applying quantum physics and artificial intelligence to enzyme engineering, secured £5 million in seed funding. PXN Ventures led the round, joined by IQ Capital and Northern Gritstone.

The company uses quantum mechanical principles combined with machine learning to design enzymes for industrial applications. This approach differs from traditional protein engineering by leveraging quantum physics to model molecular interactions at deeper levels of precision.

Enzyme engineering addresses a massive market. Industrial enzymes power sectors from pharmaceuticals to food production to sustainability applications. Current methods rely heavily on trial-and-error screening or directed evolution, both expensive and time-consuming. Imperagen's quantum-AI hybrid tackles this inefficiency.

The funding validates a thesis gaining traction in deeptech: quantum computing and physics-informed machine learning can solve hard biological problems faster than conventional methods. Companies like DeepMind have shown AI excels at protein structure prediction. Imperagen extends this by integrating quantum mechanical insights into the optimization loop.

PXN Ventures' backing signals confidence in the quantum biotech space. IQ Capital and Northern Gritstone bring experience in life sciences and emerging tech respectively. These aren't brand-name mega-funds, suggesting Imperagen positioned itself as a specialist play rather than a splashy Series A darling.

The £5 million funds hiring, lab work, and initial client partnerships. Enzyme engineering startups typically monetize through licensing deals or becoming acquisition targets for larger pharma and industrial biotech players. Genentech, DSM, and Novozymes have all acquired enzyme engineering companies in recent years, creating a clear exit path.

Imperagen enters a competitive but growing field. Synthego, Intrinsic, and others work on protein design through AI. What distinguishes Imperagen is the explicit quantum physics integration, a differentiation that could matter as enzyme design